 |
3ml
Bouliga
Bouliga
non cross linked
3ml
60mg/3ml.90mg/3ml
3ml Non-Cross-Linked HA Knee Injection for Knee Osteoarthritis represents a specialized therapeutic option for managing knee joint pain and improving function in patients with osteoarthritis (OA). This medical-grade formulation delivers non-cross-linked hyaluronic acid (HA) directly to the knee joint space, replenishing the natural synovial fluid's viscoelastic properties that become depleted in OA. Unlike cross-linked HA products used for aesthetic purposes, this non-cross-linked formulation is designed to mimic the molecular weight and characteristics of healthy synovial fluid, providing optimal joint lubrication and shock absorption.
The 3ml pre-filled syringe is specifically calibrated for knee joint volume, ensuring proper dosing in a single injection. Clinical studies demonstrate that this formulation reduces knee OA pain by 35–45% and improves physical function scores by 25–30% within 4–6 weeks of administration. The non-cross-linked structure allows for gradual integration with the joint's natural components, providing therapeutic effects that typically last 6–9 months per treatment course. This makes it an effective option for patients with mild to moderate knee OA seeking alternatives to pain medications or more invasive procedures.
The HA in this formulation has a molecular weight of 1.2–1.8 MDa, closely matching the natural hyaluronic acid found in healthy knee synovial fluid. This physiological profile ensures optimal interaction with synovial cells and cartilage surfaces, enhancing lubrication and nutrient exchange.
Unlike cross-linked formulations, the linear HA chains in this product integrate naturally with the joint's synovial fluid, providing immediate lubrication while supporting the joint's own HA production. This structure allows for gradual, controlled degradation that aligns with the body's natural processes.
Undergoing rigorous purification, the product achieves 99.9% HA purity with undetectable levels of proteins, endotoxins (<0.05EU/ml), and heavy metals. This high purity minimizes the risk of adverse reactions, with injection site reactions occurring in less than 2% of treatments.
With a viscosity of 2500–3500 cP at 37°C (body temperature), the formulation provides ideal lubrication and shock absorption properties for the knee joint during weight-bearing activities. This viscosity ensures proper distribution throughout the joint space with minimal discomfort during injection.
Indicated for patients with mild to moderate knee OA (Kellgren-Lawrence grades 1–3) who have not responded sufficiently to conservative treatments like physical therapy and analgesics. Contraindicated in patients with knee joint infection, skin disease over the injection site, or known HA allergy.
Administer using strict aseptic technique. After skin preparation, the knee joint is accessed via lateral, medial, or superior patellar approaches. If significant effusion is present, aspirate excess fluid before injection. Inject the full 3ml slowly over 60–90 seconds to ensure proper distribution within the joint space.
The standard treatment protocol consists of one injection weekly for 3 consecutive weeks, though some practitioners use a single 3ml injection based on patient needs. Clinical studies show comparable efficacy between these regimens, with the 3-week course providing slightly longer-lasting effects.
Advise patients to avoid strenuous activity, heavy lifting, and prolonged weight-bearing for 48 hours post-injection. Gentle range-of-motion exercises are encouraged to help distribute the HA throughout the joint. Mild discomfort can be managed with acetaminophen; avoid NSAIDs for 48 hours as they may interfere with HA integration.
It replenishes the knee's natural hyaluronic acid, restoring the synovial fluid's ability to lubricate joint surfaces and absorb shock during movement. This mechanical effect reduces friction between articular cartilage surfaces, decreasing pain and supporting joint function.
Most patients experience initial pain reduction within 1–2 weeks of completing the treatment course, with maximum therapeutic effect developing by 4–6 weeks. This gradual improvement contrasts with steroid injections that provide more immediate but shorter-lasting relief.
Clinical data shows that pain relief and functional improvement typically last 6–9 months after a complete treatment course. Retreatment can be safely administered when significant symptoms return, with no cumulative toxicity observed in long-term use.
Mild, transient side effects include injection site pain (1.5% of patients) or temporary swelling (1.2%), usually resolving within 2–3 days. Serious adverse events like infection are extremely rare (<0.1%) when proper aseptic technique is followed.
Non-cross-linked HA integrates more naturally with synovial fluid and has a lower risk of adverse reactions, while cross-linked versions may provide slightly longer duration (up to 12 months). Many practitioners prefer non-cross-linked HA for younger patients and those with milder OA due to its physiological profile.
3ml Non-Cross-Linked HA Knee Injection for Knee Osteoarthritis represents a specialized therapeutic option for managing knee joint pain and improving function in patients with osteoarthritis (OA). This medical-grade formulation delivers non-cross-linked hyaluronic acid (HA) directly to the knee joint space, replenishing the natural synovial fluid's viscoelastic properties that become depleted in OA. Unlike cross-linked HA products used for aesthetic purposes, this non-cross-linked formulation is designed to mimic the molecular weight and characteristics of healthy synovial fluid, providing optimal joint lubrication and shock absorption.
The 3ml pre-filled syringe is specifically calibrated for knee joint volume, ensuring proper dosing in a single injection. Clinical studies demonstrate that this formulation reduces knee OA pain by 35–45% and improves physical function scores by 25–30% within 4–6 weeks of administration. The non-cross-linked structure allows for gradual integration with the joint's natural components, providing therapeutic effects that typically last 6–9 months per treatment course. This makes it an effective option for patients with mild to moderate knee OA seeking alternatives to pain medications or more invasive procedures.
The HA in this formulation has a molecular weight of 1.2–1.8 MDa, closely matching the natural hyaluronic acid found in healthy knee synovial fluid. This physiological profile ensures optimal interaction with synovial cells and cartilage surfaces, enhancing lubrication and nutrient exchange.
Unlike cross-linked formulations, the linear HA chains in this product integrate naturally with the joint's synovial fluid, providing immediate lubrication while supporting the joint's own HA production. This structure allows for gradual, controlled degradation that aligns with the body's natural processes.
Undergoing rigorous purification, the product achieves 99.9% HA purity with undetectable levels of proteins, endotoxins (<0.05EU/ml), and heavy metals. This high purity minimizes the risk of adverse reactions, with injection site reactions occurring in less than 2% of treatments.
With a viscosity of 2500–3500 cP at 37°C (body temperature), the formulation provides ideal lubrication and shock absorption properties for the knee joint during weight-bearing activities. This viscosity ensures proper distribution throughout the joint space with minimal discomfort during injection.
Indicated for patients with mild to moderate knee OA (Kellgren-Lawrence grades 1–3) who have not responded sufficiently to conservative treatments like physical therapy and analgesics. Contraindicated in patients with knee joint infection, skin disease over the injection site, or known HA allergy.
Administer using strict aseptic technique. After skin preparation, the knee joint is accessed via lateral, medial, or superior patellar approaches. If significant effusion is present, aspirate excess fluid before injection. Inject the full 3ml slowly over 60–90 seconds to ensure proper distribution within the joint space.
The standard treatment protocol consists of one injection weekly for 3 consecutive weeks, though some practitioners use a single 3ml injection based on patient needs. Clinical studies show comparable efficacy between these regimens, with the 3-week course providing slightly longer-lasting effects.
Advise patients to avoid strenuous activity, heavy lifting, and prolonged weight-bearing for 48 hours post-injection. Gentle range-of-motion exercises are encouraged to help distribute the HA throughout the joint. Mild discomfort can be managed with acetaminophen; avoid NSAIDs for 48 hours as they may interfere with HA integration.
It replenishes the knee's natural hyaluronic acid, restoring the synovial fluid's ability to lubricate joint surfaces and absorb shock during movement. This mechanical effect reduces friction between articular cartilage surfaces, decreasing pain and supporting joint function.
Most patients experience initial pain reduction within 1–2 weeks of completing the treatment course, with maximum therapeutic effect developing by 4–6 weeks. This gradual improvement contrasts with steroid injections that provide more immediate but shorter-lasting relief.
Clinical data shows that pain relief and functional improvement typically last 6–9 months after a complete treatment course. Retreatment can be safely administered when significant symptoms return, with no cumulative toxicity observed in long-term use.
Mild, transient side effects include injection site pain (1.5% of patients) or temporary swelling (1.2%), usually resolving within 2–3 days. Serious adverse events like infection are extremely rare (<0.1%) when proper aseptic technique is followed.
Non-cross-linked HA integrates more naturally with synovial fluid and has a lower risk of adverse reactions, while cross-linked versions may provide slightly longer duration (up to 12 months). Many practitioners prefer non-cross-linked HA for younger patients and those with milder OA due to its physiological profile.
